CN Patent

CN103298806B — 取代的哒嗪羧酰胺化合物

Assigned to Zhejiang Beta Pharma Inc · Expires 2015-03-18 · 11y expired

What this patent protects

新的哒嗪衍生物具有预料之外的作为蛋白激酶抑制剂的药物特性，尤其是针对ALK，并且可用于治疗与异常蛋白激酶活性相关的紊乱，例如癌症、神经和精神疾病。

USPTO Abstract

新的哒嗪衍生物具有预料之外的作为蛋白激酶抑制剂的药物特性，尤其是针对ALK，并且可用于治疗与异常蛋白激酶活性相关的紊乱，例如癌症、神经和精神疾病。

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN103298806B
Jurisdiction: CN
Classification: —
Expires: 2015-03-18
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang Beta Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.